Navigation Links
Crizotinib reduces tumor size in patients with ALK positive lung cancer
Date:9/6/2012

Crizotinib is effective in shrinking tumors in patients with anaplastic lymphoma receptor tyrosine kinase (ALK) positive non-small cell lung cancer, a cancer commonly found in people who never smoked, and should be the standard of care for advanced stages of this disease, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago.

ALK gene rearrangements are found in around 5 percent of lung cancer tumors and are more common in people with lung cancer who never smoked. Crizotinib is an oral drug that was found to inhibit the effects of the ALK gene and to stop or reverse tumor growth.

In this phase II trial, researchers followed 901 patients for safety and 261 patients for tumor response; all of the patients had at least one prior chemotherapy treatment for their lung cancer. The overall response rate to crizotinib treatment was 60 percent and the median progression free survival (PFS) was eight months, confirming prior findings that crizotinib shrinks ALK-positive lung cancers and demonstrates a high PFS rate.

"This trial demonstrates that we have a good opportunity to shrink cancers and improve symptoms for patients with this subtype of lung cancer," said Gregory Riely, MD, PhD, lead author of the study and a medical oncologist at Memorial Sloan-Kettering Cancer Center in New York who specializes in treating lung cancer. "This confirms the results of prior studies and further shows that crizotinib can reduce the effects of symptoms, thereby improving the quality of life for thousands of patients who are diagnosed with this late-stage lung cancer. This study confirms that crizotinib is the standard of care for patients with ALK positive lung cancer."


'/>"/>

Contact: Michelle Kirkwood
michellek@astro.org
American Society for Radiation Oncology
Source:Eurekalert

Page: 1

Related medicine news :

1. Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test
2. Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women
3. Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose
4. Automated breast ultrasound dramatically reduces physician interpretation time
5. NIH study finds sigmoidoscopy reduces colorectal cancer rates
6. Surgical removal of abdominal fat reduces skin cancer in mice
7. Long-term ICS use reduces pleural effusion in patients with CAP
8. Regional anesthesia reduces complications and death for hip fracture patients
9. Surgical sling reduces risk of weakened bladder control after prolapse surgery, U-M study says
10. Single embryo transfer reduces the risk of perinatal mortality in IVF
11. HPV vaccine reduces infection, even in unvaccinated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... After raising ... FaceCradle , the most-funded travel pillow in crowdfunding history, has established ... of its wildly popular travel innovation to Americans. , “We’re excited to be operating ...
(Date:3/23/2017)... ... 2017 , ... Sharon Kleyne, host of the nationally syndicated radio program, The ... recently talked on her program about how she is looking forward to World Water ... an important distinction. World Water Day, Kleyne pointed out, is an occasion for looking ...
(Date:3/23/2017)... ... March 23, 2017 , ... Inflow IQ & Inflownomics ... serious so build on a solid foundation. As experts in dangerous situations the ... that is coming soon. Inflownomics deliver ripe, fresh, clean & refreshing knowledge systems that ...
(Date:3/23/2017)... Chatham, New Jersey (PRWEB) , ... March 23, ... ... a developer of herbal-based and non-steroidal skincare products, was awarded as winners of ... with innovation products. This competition was hosted jointly by HSN and Good Housekeeping. ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... solution, iCode Assurance, at HCCA’s 21st annual Compliance Institute on March 26-28 in ... audit process for all medical chart types with a comprehensive set of features ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Md. , March 23, 2017  The U.S. ... Bavencio (avelumab) for the treatment of adults and pediatric ... carcinoma (MCC), including those who have not received prior ... MCC, a rare, aggressive form of skin cancer. ... common cancers, patients with a rare form called Merkel ...
(Date:3/23/2017)... VANCOUVER, British Columbia , March 23, ... ) (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical ... diseases, today announced that data from its successful Phase ... a focal treatment for localized prostate cancer, will be ... the 32 nd Annual European Association of Urology ...
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... their offering. ... The global oxygen therapy devices market to grow at a CAGR ... Global Oxygen Therapy Devices Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Medicine Technology: